Announcements Trials
Browse Landscape

Phase

Phase 1/2 6Phase 1 4Phase 2 3Phase 3 1

Status

Completed 12Terminated 8Recruiting 4Unknown 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

CNS 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 173Leukemia, Myeloid, Acute 153Neoplasm Metastasis 145Neoplasms 142Breast Neoplasms 142Colorectal Neoplasms 135Recurrence 105Ovarian Neoplasms 100Pancreatic Neoplasms 81Multiple Myeloma 81Lung Neoplasms 81Advanced Solid Tumor 80Advanced Solid Tumors 74Prostatic Neoplasms 73Stomach Neoplasms 72Squamous Cell Carcinoma of Head and Neck 72Carcinoma, Hepatocellular 67Glioblastoma 65Melanoma 64Lymphoma, Non-Hodgkin 63Triple Negative Breast Neoplasms 57Myelodysplastic Syndromes 54Precursor Cell Lymphoblastic Leukemia-Lymphoma 53Lymphoma, B-Cell 53Endometrial Neoplasms 52Glioma 51Lymphoma 49Brain Neoplasms 46Hematologic Neoplasms 44Carcinoma, Renal Cell 44

Interventions

ribociclib 1palbociclib 1Radiotherapy 1Fulvestrant 1AZD1390 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1 × Recruiting × Hereditary Sensory and Autonomic Neuropathies × Clear all
NCT05683418 2026-04-22

A Study to Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast Cancer

Totus Medicines

Phase 1 Recruiting
241 enrolled
Breast

Breast Neoplasms, Hereditary Sensory and Autonomic Neuropathies

NCT06667141 2026-03-23

Phase 1 Study of ACR-2316 in Specific Advanced Solid Tumors

Acrivon Therapeutics

Phase 1 Recruiting
100 enrolled

Hereditary Sensory and Autonomic Neuropathies, Recurrence

NCT07064122 2026-03-02

A Study of AZD2962, an IRAK4 Inhibitor (IRAK4 [a Body Protein] Blocker), in Participants With Haematologic Neoplasms (Blood Cancers)

AstraZeneca

Phase 1 Recruiting
72 enrolled

Hereditary Sensory and Autonomic Neuropathies

NCT03423628 2025-12-22

A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer

AstraZeneca

Phase 1 Recruiting
180 enrolled
CNS

Brain Neoplasms, Glioblastoma, Inhibition, Psychological, Meningeal Neoplasms, Hereditary Sensory and Autonomic Neuropathies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡